天然产品在性结肠炎中调节NLRP3
Jia-Chen Xue1,2,3, Shuo Yuan2,4, Xiao-Ting Hou2
1Department of Nuclear Medicine, Affiliated Zhongshan Hospital of Dalian University, Dalian, Liaoning, China.
Frontiers in pharmacology
|October 18, 2023
概括
节点状受体蛋白3 (NLRP3) 炎症酶激活驱动性结肠炎 (UC) 炎症. 针对NLRP3的天然产品为UC治疗提供了一个有希望的治疗策略,副作用较少.
科学领域:
- 免疫学 免疫学 免疫学
- 胃肠病学 胃肠病学
- 药理学 药理学 是一个学科.
背景情况:
- 性结肠炎 (UC) 是一种具有高复发率和治疗挑战的慢性肠道炎症疾病.
- 状受体蛋白3 (NLRP3) 炎症酶因介导炎症反应而涉及UC病变发生.
- 目前的UC治疗面临的局限性包括复发和副作用,需要新的治疗方法.
研究的目的:
- 阐明NLRP3炎症酶在性结肠炎中的调节作用.
- 探索自然产品针对NLRP3进行UC处理的机制.
- 为IBD的临床诊断和治疗策略提供参考.
主要方法:
- 关于UC中NLRP3炎症酶的最近研究的综述.
- 分析NLRP3,肠道微生物和炎症之间的关系.
- 在UC模型中对NLRP3进行自然产品机制的研究.
主要成果:
- NLRP3炎症酶激活是UC发展和进展的关键因素.
- 自然产品在调节NLRP3炎症酶活性方面表现出潜在的潜力.
- 将天然产品作为NLRP3的目标,显示出对管理UC具有较少不良影响的前景.
结论:
- NLRP3炎症酶是性结肠炎的关键治疗标.
- 自然产品提供了一个可行的策略,通过针对NLRP3.3,开发新的UC治疗方法.
- 对NLRP3向性天然产品的进一步研究可能会为IBD患者改善临床结果.
相关概念视频
Drugs for Treatment of Ulcerative Colitis in IBD
149
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
149
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
338
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
338
Inflammatory Bowel Disease IV: Pharmacological Management
134
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
134
Pathophysiology of Peptic Ulcer Disease: Mucosal Defense Factors
438
Peptic ulcer disease, commonly called PUD, represents a multifaceted condition characterized by disruptions in the lining of the gastrointestinal (GI) tract. Central to the protection of the gastrointestinal lining is the mucosal-bicarbonate barrier. This physiological defense mechanism is a formidable shield against the corrosive effects of gastric acid and pepsin secretion in the stomach. Its role is pivotal in maintaining the structural integrity of the stomach's inner lining.
438
Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents
461
The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
461
Inflammatory Bowel Disease I: Ulcerative Colitis
192
Introduction
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
192


